ZEAL
Income statement / Annual
Last year (2021), Zealand Pharma A/S's total revenue was $292.57 M,
a decrease of 17.19% from the previous year.
In 2021, Zealand Pharma A/S's net income was -$1.02 B.
See Zealand Pharma A/S,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
FY-2012
|
| Period Ended |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
12/31/2013 |
12/31/2012 |
| Operating Revenue |
$292.57 M |
$353.31 M |
$41.33 M |
$37.98 M |
$139.78 M |
$234.78 M |
$187.68 M |
$153.77 M |
$6.57 M |
$223.57 M |
| Cost of Revenue |
$118.81 M
|
$90.57 M
|
$415,000.00
|
$180.24 M
|
$14.63 M
|
$31.46 M
|
$22.27 M
|
$13.78 M
|
$872,000.00
|
$15.93 M
|
| Gross Profit |
$173.75 M
|
$262.75 M
|
$40.92 M
|
-$142.26 M
|
$125.15 M
|
$203.32 M
|
$165.41 M
|
$140.00 M
|
$5.70 M
|
$207.63 M
|
| Gross Profit Ratio |
0.59
|
0.74
|
0.99
|
-3.75
|
0.9
|
0.87
|
0.88
|
0.91
|
0.87
|
0.93
|
| Research and Development Expenses |
$588.45 M
|
$604.08 M
|
$561.42 M
|
$438.22 M
|
$324.67 M
|
$268.16 M
|
$214.96 M
|
$180.04 M
|
$164.47 M
|
$182.76 M
|
| General & Administrative Expenses |
$260.99 M
|
$202.77 M
|
$67.88 M
|
$78.00 M
|
$47.47 M
|
$52.50 M
|
$44.61 M
|
$39.83 M
|
$34.16 M
|
$27.61 M
|
| Selling & Marketing Expenses |
$375.27 M
|
$285.26 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$636.26 M
|
$488.03 M
|
$67.88 M
|
$78.00 M
|
$47.47 M
|
$52.50 M
|
$44.61 M
|
$39.83 M
|
$34.16 M
|
$27.61 M
|
| Other Expenses |
-$759,000.00
|
-$602,000.00
|
-$444,000.00
|
-$630,000.00
|
-$607,000.00
|
-$1.70 M
|
-$12.83 M
|
-$6.33 M
|
-$7.30 M
|
-$35.14 M
|
| Operating Expenses |
$1.22 B
|
$1.09 B
|
$628.86 M
|
$515.59 M
|
$371.53 M
|
$318.97 M
|
$246.74 M
|
$213.53 M
|
$191.32 M
|
$175.24 M
|
| Cost And Expenses |
$1.34 B
|
$1.18 B
|
$629.28 M
|
$695.82 M
|
$386.16 M
|
$350.42 M
|
$269.00 M
|
$227.31 M
|
$192.19 M
|
$191.17 M
|
| Interest Income |
$44,000.00
|
$895,000.00
|
$5.41 M
|
$4.26 M
|
$2.05 M
|
$592,000.00
|
$139,000.00
|
$719,000.00
|
$3.04 M
|
$5.63 M
|
| Interest Expense |
$4.09 M
|
$2.90 M
|
$3.21 M
|
$15.08 M
|
$18.91 M
|
$32.16 M
|
$32.71 M
|
$2.02 M
|
$81,000.00
|
$186,000.00
|
| Depreciation & Amortization |
$40.25 M
|
$42.69 M
|
$13.68 M
|
$4.51 M
|
$4.76 M
|
$5.41 M
|
$6.22 M
|
$5.93 M
|
$5.91 M
|
$5.32 M
|
| EBITDA |
-$982.60 M |
-$794.07 M |
-$559.79 M |
$644.64 M |
-$254.10 M |
-$121.84 M |
-$80.91 M |
-$64.54 M |
-$177.68 M |
$41.88 M |
| EBITDA Ratio |
-3.36
|
-2.25
|
-13.54
|
16.97
|
-1.82
|
-0.52
|
-0.43
|
-0.42
|
-27.03
|
0.19
|
| Operating Income Ratio |
-3.5
|
-2.24
|
-14.22
|
17.18
|
-1.76
|
-0.49
|
-0.43
|
-0.48
|
-28.24
|
0.14
|
| Total Other Income/Expenses Net |
-$4.09 M
|
-$47.29 M
|
$11.27 M
|
-$27.33 M
|
-$31.39 M
|
-$43.76 M
|
-$38.51 M
|
$1.05 M
|
$1.94 M
|
$3.98 M
|
| Income Before Tax |
-$1.03 B
|
-$839.65 M
|
-$576.68 M
|
$625.06 M
|
-$277.77 M
|
-$159.41 M
|
-$119.83 M
|
-$72.49 M
|
-$183.68 M
|
$36.37 M
|
| Income Before Tax Ratio |
-3.51
|
-2.38
|
-13.95
|
16.46
|
-1.99
|
-0.68
|
-0.64
|
-0.47
|
-27.94
|
0.16
|
| Income Tax Expense |
-$8.79 M
|
$7.08 M
|
-$5.14 M
|
$43.77 M
|
-$5.50 M
|
-$5.50 M
|
-$5.88 M
|
-$7.50 M
|
$2.02 M
|
$4.16 M
|
| Net Income |
-$1.02 B
|
-$846.73 M
|
-$571.54 M
|
$581.28 M
|
-$272.27 M
|
-$153.91 M
|
-$113.96 M
|
-$64.99 M
|
-$183.68 M
|
$36.37 M
|
| Net Income Ratio |
-3.48
|
-2.4
|
-13.83
|
15.31
|
-1.95
|
-0.66
|
-0.61
|
-0.42
|
-27.94
|
0.16
|
| EPS |
-26.54 |
-22.07 |
-16.91 |
18.94 |
-9.77 |
-6.33 |
-4.82 |
-2.87 |
-8.12 |
1.61 |
| EPS Diluted |
-26.54 |
-22.07 |
-16.91 |
18.94 |
-9.77 |
-6.33 |
-4.82 |
-2.87 |
-8.12 |
1.6 |
| Weighted Average Shares Out |
$38.37 M
|
$38.37 M
|
$33.80 M
|
$30.70 M
|
$27.85 M
|
$24.31 M
|
$23.64 M
|
$22.63 M
|
$22.63 M
|
$22.63 M
|
| Weighted Average Shares Out Diluted |
$38.37 M
|
$38.37 M
|
$33.80 M
|
$30.70 M
|
$27.85 M
|
$24.31 M
|
$23.64 M
|
$22.63 M
|
$22.63 M
|
$22.73 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
